We suppose that a standard molecular analysis performed (IDH, EGFR, p53 and Ki-67) are not sufficient to predict the behavior of a GBM regard to OS and a deeper understanding of the meaning of the different genetic alterations in the DNA of cancer cells, and a study with MGMT data included, will allow a more accurate prognostic stratification of the single patient resulting in a patient-specific therapeutic approach. This evidence concerns the gene IDH1 and glioblastoma.